查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1938883

腦腫瘤診斷市場 - 全球產業規模、佔有率、趨勢、機會及預測（按診斷類型、腫瘤類型、最終用戶、地區和競爭格局分類，2021-2031年）

Brain Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnostic Type, By Tumor Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球腦瘤診斷市場預計將從 2025 年的 36.7 億美元成長到 2031 年的 46.8 億美元，複合年成長率為 4.13%。

此領域涵蓋用於識別和表徵顱內腫瘤的各種醫療技術，包括磁振造影(MRI)、電腦斷層掃描 (CT) 和分子檢測。推動該市場發展的主要因素是對及時、準確疾病檢測日益成長的需求，而全球人口老化和中樞神經系統疾病發病率的上升加劇了這一需求。美國癌症協會估計，到 2025 年，美國將診斷出 24,820 例惡性腦或脊髓腫瘤病例，凸顯了有效診斷能力的重要性，也印證了這一緊迫性。

市場概覽
預測期 2027-2031
市場規模：2025年 36.7億美元
市場規模：2031年 46.8億美元
複合年成長率：2026-2031年 4.13%
成長最快的細分市場 影像檢查
最大的市場 北美洲

儘管市場成長前景良好，但由於尖端診斷程序的高昂成本，市場仍面臨許多障礙。高解析度成像和基因組分析所需的巨額費用常常限制了患者的就醫和接受度，尤其是在醫療報銷有限的地區。這種經濟限制是主要阻礙因素，可能會阻礙這些重要診斷工具在全球更廣泛的應用。

市場促進因素

將人工智慧 (AI) 整合到診斷工作流程中是推動市場發展的關鍵因素，顯著提高了顱內腫瘤辨識的準確性和效率。 AI 演算法正被擴大用於自動化 MRI 影像中複雜的腫瘤分割任務，其區分惡性組織、水腫和正常腦組織的精確度遠高於人工方法。這項技術進步滿足了快速制定治療方案的迫切需求，同時最大限度地減少了放射科醫生之間的差異。為了展示這項進展，Sora Neuroscience 於 2025 年 6 月宣布，其 AI 驅動的工具 Cirrus 靜息態 fMRI 軟體已獲得 FDA核准。該軟體能夠快速繪製關鍵腦功能圖，旨在改善手術決策並提高腫瘤切除術的安全性。

同時，非侵入性液態生物檢體技術的興起正在重塑市場格局，為高風險手術提供了更安全的替代方案。這些創新技術能夠檢測穿過血腦障壁的循環腫瘤DNA，從而無需進行侵入性顱內手術即可實現疾病進展的即時追蹤和分子分析。 2025年9月，腦腫瘤研究資助聯盟發布研究津貼聲明，向多機構研究團隊撥款100萬美元，用於推動原發性腦腫瘤液態生物檢體技術的發展。這項進展得到了大量投資的支持：據美國國家腦腫瘤協會稱，美國國立衛生研究院預計將在2025年撥款5.18億美元用於腦腫瘤研究，這為推進這些診斷技術的發展提供了關鍵的資金支持。

市場挑戰

先進診斷程序的高昂成本是全球腦腫瘤診斷市場發展的主要障礙。高場磁振造影和分子生物標記分析等尖端技術需要大量資金投入，導致醫療機構和患者都面臨高昂的費用。在開發中國家和健保體系薄弱的地區，這種經濟負擔限制了患者獲得重要檢測的機會，並有效地阻礙了這些診斷工具的廣泛應用。因此，價格敏感地區的市場滲透率仍然很低，而醫療資源豐富的已開發國家仍產生收入。

鑑於需要對顱內腫瘤進行全面鑑別診斷的患者群體龐大，此經濟障礙尤其具有限制性。高成本造成了瓶頸，抑制了此類疾病高發生率所帶來的潛在需求。根據美國國家腦瘤協會估計，2024年美國將診斷出約9萬例原發性腦腫瘤。這項數據凸顯了龐大的臨床診斷需求，但由於資金限制，這些需求仍未得到充分滿足，直接阻礙了市場充分利用中樞神經系統疾病日益成長的趨勢。

市場趨勢

DNA甲基化譜分析的應用正在革新中樞神經系統腫瘤的分子分型，其診斷準確性遠超傳統組織病理學。這種表觀遺傳學方法透過分析DNA上的化學修飾來識別特定的腫瘤類型。它尤其適用於標準顯微鏡分析無法得出結論的複雜病例。透過將甲基化特徵納入診斷框架，臨床醫師可以更準確地對膠質瘤和生殖細胞腫瘤進行亞型分類，直接促進個人化治療方案的發展。 2025年12月，德國癌症研究中心（DKFZ）宣布，最新版本的海德堡中樞神經系統腫瘤甲基化分類器能夠區分超過180種腫瘤類型，其鑑別能力較上一版本提高了一倍，顯著拓展了精準分子診斷的潛力。

同時，照護現場解決方案的出現，透過將攜帶式低場磁振造影（MRI）設備引入重症監護環境，提高了神經影像學的可及性。與需要屏蔽室和病患轉運的傳統高場核磁共振造影系統不同，這些行動裝置可在加護病房）和急診室（ER）的床邊進行設置和操作，從而能夠快速評估腦部病變。這一趨勢緩解了可用掃描儀短缺的問題，並降低了轉運嚴重患者的後勤風險。正如Fierce Biotech在2025年7月報導的那樣，Hyperfine已開始商業化部署其獲得FDA批准的下一代可攜式MRI系統「Swoop」。這項研發旨在擴展即時神經影像學能力，尤其是在資源有限的臨床環境中。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球腦腫瘤診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依診斷方法（影像檢查、腰椎穿刺、切片檢查、分子檢測、其他）
    • 依腫瘤類型（轉移性腫瘤、腦膜瘤、膠質母細胞瘤、腦下垂體瘤、其他）
    • 依最終使用者（醫院、診斷中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美腦腫瘤診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲腦腫瘤診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區腦腫瘤診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲腦腫瘤診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章 南美洲腦腫瘤診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球腦腫瘤診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • GE Healthcare Inc
  • Koninklijke Philips NV
  • Siemens Healthineers AG
  • Fujifilm Corp
  • Hitachi, Ltd.
  • Hologic Inc
  • NantOmics LLC
  • Thermo Fisher Scientific Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19539

The Global Brain Cancer Diagnostics Market is projected to expand from USD 3.67 Billion in 2025 to USD 4.68 Billion by 2031, reflecting a compound annual growth rate of 4.13%. This sector encompasses a diverse array of medical technologies, such as magnetic resonance imaging, computed tomography, and molecular assays, all utilized to identify and characterize intracranial neoplasms. The primary catalyst driving this market is the escalating demand for timely and accurate disease detection, a need intensified by an aging global population and the rising frequency of central nervous system disorders. To highlight this urgency, the American Cancer Society estimated that 24,820 malignant brain or spinal cord tumors would be diagnosed in the United States in 2025, underscoring the critical necessity for effective diagnostic capabilities.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.67 Billion
Market Size 2031USD 4.68 Billion
CAGR 2026-20314.13%
Fastest Growing SegmentImaging Test
Largest MarketNorth America

Despite these favorable growth prospects, the market confronts substantial hurdles stemming from the exorbitant costs associated with cutting-edge diagnostic procedures. The significant financial outlay required for high-resolution imaging and genomic profiling frequently restricts patient access and adoption rates, particularly in regions where healthcare reimbursement structures are limited. This economic constraint serves as a major restraint, potentially obstructing the broader global dissemination and utilization of these essential diagnostic instruments.

Market Driver

The incorporation of Artificial Intelligence into diagnostic workflows acts as a major market driver by substantially improving the accuracy and efficiency of identifying intracranial neoplasms. AI algorithms are increasingly utilized to automate complex tumor segmentation tasks within MRI scans, differentiating between malignant tissues, edema, and healthy brain matter with a level of precision that exceeds manual methods. This technological evolution satisfies the urgent requirement for rapid treatment planning while minimizing variability between radiologists. Illustrating this advancement, Sora Neuroscience announced in June 2025 the FDA clearance of its Cirrus Resting State fMRI Software, an AI-driven tool designed to quickly map essential brain functions, thereby enhancing surgical decision-making and increasing safety during tumor resections.

Simultaneously, the shift toward non-invasive liquid biopsy techniques is reshaping the market by providing safer alternatives to high-risk surgical procedures. These innovations enable the detection of circulating tumor DNA across the blood-brain barrier, allowing for real-time tracking of disease progression and molecular profiling without invasive cranial interventions. In September 2025, the Brain Tumor Funders' Collaborative released a statement regarding research grants, awarding $1 million to multi-institutional teams specifically to further liquid biopsy technologies for primary brain tumors. This progress is supported by significant investment; the National Brain Tumor Society reported that in 2025, the National Institutes of Health was projected to contribute $518 million toward brain cancer research, demonstrating the vital financial backing propelling these diagnostic capabilities forward.

Market Challenge

The elevated expense associated with advanced diagnostic procedures poses a considerable obstacle to the growth of the Global Brain Cancer Diagnostics Market. State-of-the-art modalities, including high-field magnetic resonance imaging and molecular biomarker profiling, necessitate massive capital expenditures, resulting in high costs for both healthcare providers and patients. In developing nations and regions with insufficient reimbursement systems, these financial demands curtail access to critical testing, effectively hindering the widespread implementation of these tools. As a result, market penetration in price-sensitive sectors remains low, confining significant revenue generation largely to developed economies with strong healthcare funding.

This economic barrier is especially restrictive considering the substantial number of patients needing precise differentiation of intracranial neoplasms. The high cost creates a bottleneck that stifles the potential demand generated by the prevalence of these conditions. According to the National Brain Tumor Society, an estimated 90,000 primary brain tumors were diagnosed in the United States in 2024. This statistic highlights the immense clinical necessity for diagnostics that remains partially unmet due to financial constraints, directly impeding the market's capacity to fully leverage the increasing incidence of central nervous system disorders.

Market Trends

The adoption of DNA methylation profiling is transforming the molecular classification of central nervous system tumors by providing diagnostic clarity superior to conventional histopathology. This epigenetic method examines chemical modifications on DNA to distinguish specific tumor entities, proving particularly valuable in complex cases where standard microscopic analysis yields inconclusive results. By incorporating methylation signatures into diagnostic frameworks, clinicians can attain greater precision in sub-typing gliomas and embryonal tumors, which directly informs personalized treatment plans. In December 2025, the German Cancer Research Center (DKFZ) announced that the newest iteration of its Heidelberg CNS Tumor Methylation Classifier could identify over 180 tumor types, doubling the capacity of the previous version and significantly broadening the horizon of precise molecular diagnosis.

In parallel, the emergence of point-of-care diagnostic solutions is making neuroimaging more accessible through the deployment of portable, low-field magnetic resonance imaging systems in critical care environments. Unlike traditional high-field MRI units that demand shielded rooms and patient transport, these mobile devices can be operated bedside in intensive care units and emergency rooms, allowing for the swift evaluation of brain pathology. This trend mitigates the shortage of available scanners and lowers the logistical risks involved in moving critically ill patients. As reported by Fierce Biotech in July 2025, Hyperfine began the commercial rollout of its FDA-cleared next-generation Swoop portable MRI system, a development specifically focused on extending immediate neuroimaging capabilities to resource-limited clinical settings.

Key Market Players

  • GE Healthcare Inc
  • Koninklijke Philips NV
  • Siemens Healthineers AG
  • Fujifilm Corp
  • Hitachi, Ltd.
  • Hologic Inc
  • NantOmics LLC
  • Thermo Fisher Scientific Inc

Report Scope

In this report, the Global Brain Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Brain Cancer Diagnostics Market, By Diagnostic Type

  • Imaging Test
  • Lumbar Puncture
  • Biopsy
  • Molecular Testing
  • Others

Brain Cancer Diagnostics Market, By Tumor Type

  • Metastatic
  • Meningioma
  • Glioblastoma
  • Pituitary Endoma
  • Others

Brain Cancer Diagnostics Market, By End User

  • Hospitals
  • Diagnostics Centers
  • Others

Brain Cancer Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Brain Cancer Diagnostics Market.

Available Customizations:

Global Brain Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Brain Cancer Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Diagnostic Type (Imaging Test, Lumbar Puncture, Biopsy, Molecular Testing, Others)
    • 5.2.2. By Tumor Type (Metastatic, Meningioma, Glioblastoma, Pituitary Endoma, Others)
    • 5.2.3. By End User (Hospitals, Diagnostics Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Brain Cancer Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Diagnostic Type
    • 6.2.2. By Tumor Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Brain Cancer Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Diagnostic Type
        • 6.3.1.2.2. By Tumor Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Brain Cancer Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Diagnostic Type
        • 6.3.2.2.2. By Tumor Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Brain Cancer Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Diagnostic Type
        • 6.3.3.2.2. By Tumor Type
        • 6.3.3.2.3. By End User

7. Europe Brain Cancer Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Diagnostic Type
    • 7.2.2. By Tumor Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Brain Cancer Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Diagnostic Type
        • 7.3.1.2.2. By Tumor Type
        • 7.3.1.2.3. By End User
    • 7.3.2. France Brain Cancer Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Diagnostic Type
        • 7.3.2.2.2. By Tumor Type
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Brain Cancer Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Diagnostic Type
        • 7.3.3.2.2. By Tumor Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Brain Cancer Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Diagnostic Type
        • 7.3.4.2.2. By Tumor Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Brain Cancer Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Diagnostic Type
        • 7.3.5.2.2. By Tumor Type
        • 7.3.5.2.3. By End User

8. Asia Pacific Brain Cancer Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Diagnostic Type
    • 8.2.2. By Tumor Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Brain Cancer Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Diagnostic Type
        • 8.3.1.2.2. By Tumor Type
        • 8.3.1.2.3. By End User
    • 8.3.2. India Brain Cancer Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Diagnostic Type
        • 8.3.2.2.2. By Tumor Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Brain Cancer Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Diagnostic Type
        • 8.3.3.2.2. By Tumor Type
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Brain Cancer Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Diagnostic Type
        • 8.3.4.2.2. By Tumor Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Brain Cancer Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Diagnostic Type
        • 8.3.5.2.2. By Tumor Type
        • 8.3.5.2.3. By End User

9. Middle East & Africa Brain Cancer Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Diagnostic Type
    • 9.2.2. By Tumor Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Brain Cancer Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Diagnostic Type
        • 9.3.1.2.2. By Tumor Type
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Brain Cancer Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Diagnostic Type
        • 9.3.2.2.2. By Tumor Type
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Brain Cancer Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Diagnostic Type
        • 9.3.3.2.2. By Tumor Type
        • 9.3.3.2.3. By End User

10. South America Brain Cancer Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Diagnostic Type
    • 10.2.2. By Tumor Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Brain Cancer Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Diagnostic Type
        • 10.3.1.2.2. By Tumor Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Brain Cancer Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Diagnostic Type
        • 10.3.2.2.2. By Tumor Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Brain Cancer Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Diagnostic Type
        • 10.3.3.2.2. By Tumor Type
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Brain Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GE Healthcare Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Koninklijke Philips NV
  • 15.3. Siemens Healthineers AG
  • 15.4. Fujifilm Corp
  • 15.5. Hitachi, Ltd.
  • 15.6. Hologic Inc
  • 15.7. NantOmics LLC
  • 15.8. Thermo Fisher Scientific Inc

16. Strategic Recommendations

17. About Us & Disclaimer